Cargando…
HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
BACKGROUND: The efficacy of licensed direct-acting antiviral (DAA) regimens is assumed to be the same for hepatitis C virus (HCV)–monoinfected patients (HCV-Mono) and HIV/HCV-coinfected patients (HCV-Co). However, the high sustained viral response (SVR) rates of DAA regimens and the small number of...
Autores principales: | Berenguer, Juan, Calleja, José Luis, Montes, María Luisa, Gil, Ángela, Moreno, Ana, Bañares, Rafael, Aldámiz-Echevarría, Teresa, Albillos, Agustín, Téllez, María Jesús, Olveira, Antonio, Domínguez, Lourdes, Fernández, Inmaculada, García-Samaniego, Javier, Polo, Benjamín A, Álvarez, Beatriz, Ryan, Pablo, Barrio, José, Devesa, María J, Benítez, Laura, Santos, Ignacio, Buey, Luisa García, Sanz, José, Poves, Elvira, Losa, Juan E, Fernández-Rodríguez, Conrado, Jarrín, Inmaculada, Calvo, María J, González-García, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534283/ https://www.ncbi.nlm.nih.gov/pubmed/31139679 http://dx.doi.org/10.1093/ofid/ofz214 |
Ejemplares similares
-
Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data
por: Andres, Jennifer, et al.
Publicado: (2018) -
Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018) -
Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017) -
Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017) -
Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)